Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Variants & evidence
522 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| KIT D816H2 | |||||||
| Bosutinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4153In an in vitro study, the recombinant KIT D816H mutation kinase was associated with increased sensitivity to bosutinib treatment (IC50: 32nM), as compared to wild-type KIT (IC50: 6313 nM). Sensitivit… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4154In an in vitro study, the recombinant KIT D816H mutation kinase was associated with increased sensitivity to dasatinib treatment(IC50: 2.6nM vs. 93.0nM), as compared to the wild-type KIT kinase. Sensi… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| KIT D816V6 | |||||||
| Bosutinib | Predictive | D | Supports Resistance | — | submitted | EID4161In an in vitro study, the recombinant KIT D816V mutation kinase was associated with insensitivity to bosutinib treatment (IC50: 2772nM), comparable to wild-type KIT kinase (IC50: 6313nM). Resistance w… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID8361In the HMC-1 human cell line, cells with KIT V560G activating mutation were treated with dasatinib and showed reduced levels of phospho-KIT, potent growth inhibition, and increased Annexin V binding a… (full text at CIViC) PMID 16434489 · Shah et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | — | submitted | EID4162In an in vitro study, the recombinant KIT D816V mutation kinase was associated with increased sensitivity to dasatinib treatment (IC50: 37nM vs. 79nM), as compared to wild-type KIT kinase. Sensitivity… | |
| KIT M541L1 | |||||||
| (diagnostic) | Diagnostic | B | Does Not Support Positive | 4 | accepted | EID485M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was … (full text at CIViC) PMID 16307017 · Krüger et al., 2006 · Open in CIViC | civic |
| KIT V560G2 | |||||||
| Bosutinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4134In an in vitro study, the recombinant KIT V560G mutation kinase was associated with increased sensitivity to bosutinib treatment (IC50: 181nM), as compared to wild-type KIT kinase (IC50: 6313nM). Sens… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4135In an in vitro study, the recombinant KIT V560G mutation kinase was associated with increased sensitivity to dasatinib treatment (IC50: 1.5nM vs 93.0nM), as compared to wild-type KIT kinase. Sensitivi… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| KIT V654A2 | |||||||
| Bosutinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4149In an in vitro study, the recombinant KIT V654A mutation was associated with increased sensitivity to bosutinib treatment (IC50:132 nM), as compared to wild-type KIT kinase (IC50: 6313 nM). Sensitivi… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4150In an in vitro study, the recombinant KIT V654A mutation was associated with increased sensitivity to dasatinib treatment (IC50: 4.2nM vs, 93.0nM), as compared to wild-type KIT kinase. Sensitivity was… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| LYN OVEREXPRESSION2 | |||||||
| Bafetinib + DasatinibSubstitutes | Predictive | D | Does Not Support Resistance | 3 | accepted | EID7874The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Dasatinib showed the most potency against MYL-R compared to the non-resistant MYL cell line (IC50: 6… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC | civic |
| Nilotinib | Predictive | D | Supports Resistance | 1 | accepted | EID7875The BCR-ABL1 expressing imatinib-resistant cell line MYL-R overexpresses LYN, an SRC family kinase. Nilotinib showed 3.1 times less potency than bafetinib (INNO-406) against MYL-R (IC50: 993.6 nM vs. … (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC | civic |
| LYN Y508F2 | |||||||
| Axitinib | Predictive | D | Supports Sensitivity Response | — | submitted | EID4804In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to axitinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was determ… (full text at CIViC) PMID 26912052 · Halbach et al., 2016 · Open in CIViC | civic |
| Dasatinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID4805In an in vitro study, a K562 cell line expressing LYN Y508F mutation demonstrated sensitivity to dasatinib treatment, comparable to K562 cells expressing wild-type LYN or vector. Sensitivity was deter… (full text at CIViC) PMID 26912052 · Halbach et al., 2016 · Open in CIViC | civic |
| NTRK2 R458G1 | |||||||
| Crizotinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID8609The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical mechanisms that may involve altered interactions between the mutant receptor and lipids in t… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC | civic |
| PDGFRA D842V1 | |||||||
| Bosutinib | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID7514In an in vitro kinase study, the recombinant PDGFRA D842V mutant kinase demonstrated sensitivity to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 25 and 6) when compared to wild t… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| RET V804M1 | |||||||
| Dasatinib | Predictive | D | Supports Resistance | 2 | submitted | EID7516In an in vitro kinase study, the recombinant RET V804M mutant kinase demonstrated resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 99 and 87) when compared to wild type… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| SETBP1 G870S1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | accepted | EID840Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor p… (full text at CIViC) PMID 23222956 · Piazza et al., 2013 · Open in CIViC | civic |
| TEK R849W1 | |||||||
| Bosutinib | Predictive | D | Supports Resistance | 2 | submitted | EID7517In an in vitro kinase study, the recombinant TEK R849W mutant kinase demonstrated resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 77 and 35) when compared to wild type… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
Data updated 18 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 16434489 · Shah et al., 2006 · Open in CIViC
| civic |
| 〃 | Predictive | D | Supports Sensitivity Response | — | submitted | EID4163In an in vitro study, the recombinant KIT D816V mutation kinase was associated with sensitivity to dasatinib treatment. PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC | civic |
| Imatinib | Predictive | D | Supports Resistance | 4 | accepted | EID8360In an in vitro kinase experiment, kinases wtih the KIT D816V mutation demonstrated resistance to imatinib (IC50: >10,000nM vs. 1550nM) treatment compared to the KIT wild-type kinase. In the HMC-1 huma… (full text at CIViC) PMID 16434489 · Shah et al., 2006 · Open in CIViC | civic |
| 〃 | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID8362In the HMC-1 human cell line, cells with KIT V560G activating mutation were treated with imatinib and showed reduced levels of phospho-KIT, potent growth inhibition, and increased Annexin V binding at… (full text at CIViC) PMID 16434489 · Shah et al., 2006 · Open in CIViC | civic |